Compare RTO & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTO | VTRS |
|---|---|---|
| Founded | 1925 | 1961 |
| Country | United Kingdom | United States |
| Employees | 65632 | 30000 |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 17.2B |
| IPO Year | N/A | 2019 |
| Metric | RTO | VTRS |
|---|---|---|
| Price | $30.74 | $13.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $35.00 | $13.00 |
| AVG Volume (30 Days) | 1.7M | ★ 9.6M |
| Earning Date | 03-09-2026 | 05-07-2026 |
| Dividend Yield | 1.67% | ★ 3.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | $17.39 | $4.45 |
| Revenue Next Year | $6.25 | $1.79 |
| P/E Ratio | $222.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.60 | $6.85 |
| 52 Week High | $33.47 | $16.47 |
| Indicator | RTO | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 32.97 |
| Support Level | $29.31 | $12.92 |
| Resistance Level | $32.79 | $13.49 |
| Average True Range (ATR) | 0.72 | 0.42 |
| MACD | -0.00 | -0.19 |
| Stochastic Oscillator | 47.16 | 4.82 |
Rentokil Initial is the largest global provider of route-based pest control and commercial hygiene services, operating in over 90 countries, with its largest operations in the United States following the acquisition of Terminix. The group also offers a range of specialist route-based services, including office and commercial space plant care, property care, and workwear rentals. The group serves a diverse client base of global food producers, hotel chains, industrial goods companies, restaurants, and individual residential customers.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.